Shareholders of VERAXA Biotech (NASDAQ: VRXA) have voted overwhelmingly in favor of all proposals presented at the company's Extraordinary General Meeting, with more than 99.94% of votes cast in support and 72.20% of outstanding share capital represented. The approved measures include the introduction of conditional share capital for shareholder options and warrants, implementation of a capital band through Dec. 31, 2030, and an increase in the maximum board size from five to seven members.
The company stated that the enhanced corporate and financing framework is intended to support its long-term growth strategy by providing greater flexibility for potential acquisitions, strategic collaborations, investment projects, capital markets activities, and continued development of its BiTAC(R) technology platform and oncology pipeline. Management indicated that the vote reflects strong shareholder confidence in VERAXA’s strategy of advancing antibody-based cancer therapeutics while pursuing long-term value creation.
VERAXA Biotech is focused on building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs, and other innovative formats. Powered by transformative technologies and guided by quality-by-design principles, the company is rapidly advancing its pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology.
The approval of these measures is significant for the company's future. The capital band and conditional share capital provide the board with tools to raise funds or issue shares for acquisitions without requiring additional shareholder meetings, expediting strategic moves. The expanded board size allows for the addition of directors with specialized expertise in oncology, finance, or corporate development, which could enhance governance and strategic oversight.
Investors and stakeholders can view the full press release at https://ibn.fm/qfL87. For the latest news and updates relating to VRXA, visit the company’s newsroom at https://ibn.fm/VRXA.
This development underscores VERAXA's commitment to advancing its oncology pipeline and creating shareholder value. The strong shareholder support provides a solid foundation for the company to pursue its strategic objectives in the competitive biotech landscape.
